|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
PacificGMP and University of Southern California to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
7/27/2009 9:46:07 AM
SAN DIEGO and LOS ANGELES, July 27 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, and the University of Southern California (USC) announced today that they have signed an agreement whereby PacificGMP will provide development and manufacturing services for USC. Under terms of the agreement, PacificGMP will provide process scale up development, cGMP (current good manufacturing practices) manufacturing and aseptic fill and finish of purified human recombinant type VII collagen. The recombinant protein will be tested in a Phase 1 clinical trial for treatment of dystrophic epidermal bullosa (DEB), a rare disease in children born with defects in the gene that encodes type VII collagen. DEB is characterized by extremely fragile skin, recurrent blister formation, scarring and aggressive squamous cell carcinomas. Keck School of Medicine of the University of Southern California researchers David T. Woodley, M.D. and Mei Chen, Ph.D. have studied various therapeutic strategies for DEB and are the principal investigators for the study.
|
|
|
|
|
|
|
|
|
|
|